#USA #Chicago #Atrium Therapeutics #PRKAG2 Syndrome #ATR 1072

Atrium Therapeutics Introduces Groundbreaking Findings on ATR 1072

Atrium Therapeutics, Inc., a leading player in the biopharmaceutical domain focusing on precision cardiology, is set to present compelling new nonclinical data regarding its investigational therapy, ATR 1072, aimed at treating PRKAG2 syndrome. This noteworthy presentation will take place at the Hypertrophic Cardiomyopathy Medical Society (HCMS) during the American Heart Association Scientific Sessions on November 6, 2026, in the vibrant city of Chicago, Illinois.

Understanding PRKAG2 Syndrome

PRKAG2 syndrome is a rare hereditary condition characterized as an early-onset cardiomyopathy. It stems from mutations in the PRKAG2 gene, which is crucial for the regulation of AMP-activated protein kinase (AMPK). These mutations lead to heightened AMPK activity, resulting in abnormal glycogen buildup in the heart and thickened heart walls, ultimately causing electrical conduction issues and raising the risk of arrhythmias. Current estimates suggest that between 1,000 to 2,000 individuals suffer from PRKAG2 syndrome in the U.S., with no approved therapies available to tackle the fundamental genetic cause.

The Innovation behind ATR 1072

The nonclinical results to be shared by Atrium highlighted a successful approach using a new mouse model that closely simulates various aspects of PRKAG2 syndrome. This model has provided critical insights into the potential effectiveness of ATR 1072, revealing its ability to reverse the buildup of cardiac glycogen and improve other related symptoms. Husam Younis, the Chief Scientific Officer at Atrium, expressed optimism regarding these developments, stating that they offer substantial reinforcement for the scientific rationale behind targeting PRKAG2 genes in the heart with ATR 1072.

In a controlled study, mice were administered a singular dose of a mouse-specific variant of ATR 1072 after three weeks of established disease features. The results were promising: treatment not only reduced glycogen accumulation but also improved cardiac hypertrophy and corrected discrepancies reflected in electrocardiogram readings.

Upcoming Clinical Trials

These exciting preliminary discoveries bolster Atrium's plans for future clinical exploration, particularly the ongoing Phase 1/2 Corventis trial. This important trial is designed to investigate the safety, pharmacokinetics, and initial efficacy of ATR 1072 in individuals diagnosed with PRKAG2 syndrome. The Corventis trial plans to enroll roughly 37 participants, offering deeper insights into treatment impacts while maintaining a focus on safety and tolerability.

Key Details of the HCMS Presentation

During the HCMS Scientific Sessions, Atrium will present findings under the title: Targeting PRKAG2 mRNA with mATR 1072 to improve glycogen-storage cardiomyopathy in a mouse model of PRKAG2 syndrome. This session is expected to attract significant interest given its focus on a unique approach to targeting genetic cardiomyopathies.

A Glimpse into Atrium’s Vision

Atrium Therapeutics is redefining the landscape of cardiovascular treatment through its innovative approach to RNA therapeutics. The company utilizes proprietary technology designed at Avidity Biosciences, merging the targeting ability of monoclonal antibodies with the precision of RNA oligonucleotides. This novel delivery method aims to overcome challenges typically linked to non-specific tissue targeting, making it possible to effectively deliver RNA therapeutics directly to the heart. Following ATR 1072, Atrium also has developments underway for other conditions, including ATR 1086 intended for PLN cardiomyopathy.

In conclusion, Atrium Therapeutics is paving the way for a new paradigm in treating genetically driven heart conditions, providing hope where few options currently exist. With results from the Corventis trial anticipated in the latter half of 2027, the scientific community, alongside patients, will keenly await the implications of ATR 1072 and the future of treatments for PRKAG2 syndrome.